Structure Therapeutics, Inc. (GPCR)
25.70
+0.03
(+0.12%)
USD |
NASDAQ |
Oct 09, 13:29
Structure Therapeutics Free Cash Flow : -225.05M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -225.05M |
| March 31, 2026 | -159.70M |
| December 31, 2025 | -226.41M |
| September 30, 2025 | -196.67M |
| June 30, 2025 | -164.60M |
| March 31, 2025 | -136.42M |
| Date | Value |
|---|---|
| December 31, 2024 | -117.99M |
| September 30, 2024 | -104.60M |
| June 30, 2024 | -105.58M |
| March 31, 2024 | -95.59M |
| December 31, 2023 | -81.58M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Eli Lilly & Co. | 13.56B |
| Novo Nordisk A/S | 7.517B |
| Pfizer Inc. | 10.99B |
| Viking Therapeutics, Inc. | -418.44M |
| Liquidia Corp. | 150.69M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -120.38M |
| Cash from Investing (Quarterly) | 75.10M |
| Cash from Financing (Quarterly) | 2.091M |
| Free Cash Flow Per Share (Quarterly) | -1.656 |
| Free Cash Flow to Equity (Quarterly) | -120.77M |
| Free Cash Flow to Firm (Quarterly) | -120.34M |
| Free Cash Flow Yield | -13.33% |